(R)-(-)-Ketamine hydrochloride

Discontinued Product

6751 has been discontinued.

View all Ketamine and Metabolites products.
Description: NMDA antagonist; antidepressant; may not display psychotomimetic or addictive side effects of (S)-ketamine
Chemical Name: (R)-(-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature (2)

Biological Activity for (R)-(-)-Ketamine hydrochloride

(R)-(-)-Ketamine hydrochloride is a NMDA antagonist (Ki = 1.4 μM); exhibits more potent and longer lasting antidepressant effects compared to its enantiomer (S)-ketamine in vivo. Also may not display the psychotomimetic or addictive side effects associated with (S)-ketamine. (R)-(-)-Ketamine hydrochloride upregulates KCNQ2 channels in mouse ventral hippocampal glutamatergic neurons in vitro and in vivo. It exerts its sustained antidepressant effetcs via KCNQ2 cell type specific regulation.

Technical Data for (R)-(-)-Ketamine hydrochloride

M. Wt 274.19
Formula C13H16ClNO.HCl
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 33795-24-3
PubChem ID 9838417
InChI Key VCMGMSHEPQENPE-BTQNPOSSSA-N
Smiles O=C1[C@@](C2=CC=CC=C2Cl)(NC)CCCC1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (R)-(-)-Ketamine hydrochloride

References for (R)-(-)-Ketamine hydrochloride

References are publications that support the biological activity of the product.

Zhang et al (2014) R-(-)-ketamine shows greater potency and longer lasting antidepressant effects than S-(+)-ketamine. Pharmacol.Biochem.Behav. 116 137 PMID: 24316345

Xiong et al (2018) Comparison of rapid and long-lasting antidepressant effects of negative modulators of α5-containing GABAA receptors and (R)-ketamine in a chronic social defeat stress model. Pharmacol.Biochem.Behav. 175 139 PMID: 30359627

Zanos et al (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 481 PMID: 27144355

Ebert et al (1997) Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur.J.Pharmacol. 333 99 PMID: 9311667

Lopez et al (2022) Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2. Neuron 110 2283 PMID: 35649415

Keywords: (R)-(-)-Ketamine hydrochloride, (R)-(-)-Ketamine hydrochloride supplier, NMDA, receptor, antagonists, antagonism, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, ketamine, Ketamine, and, Metabolites, 6751, Tocris Bioscience

Citations for (R)-(-)-Ketamine hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for (R)-(-)-Ketamine hydrochloride.

Reviews for (R)-(-)-Ketamine hydrochloride

There are currently no reviews for this product. Be the first to review (R)-(-)-Ketamine hydrochloride and earn rewards!

Have you used (R)-(-)-Ketamine hydrochloride?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.